| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193452 | Journal of Thoracic Oncology | 2014 | 10 Pages |
Abstract
Discovery of HIP1 as a fusion partner of ALK in NSCLC is a novel finding. In addition, the HIP1-ALK-rearranged tumor is sensitive to treatment with crizotinib in vivo, implicating HIP1-ALKas an oncogenic driver of lung tumorigenesis. Collectively, our results indicate that HIP1-ALK-positive NSCLC may benefit from clinical applications of crizotinib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Douglas D. PhD, Bin PhD, Qingyang PhD, Maruja BS, Qiang PhD, Hongye PhD, Maoxiang PhD, Weiqi MD, PhD, Mark BS, Zhenxiong PhD, Cathy MS, Xinsheng MS, Kevin X. PhD, Jian PhD, Shu-Hui PhD, James PhD, Mao MD, PhD, Chi-Chung PhD,